Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,793,679
  • Shares Outstanding, K 63,696
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,500 K
  • 60-Month Beta 0.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.04
  • Number of Estimates 3
  • High Estimate -0.93
  • Low Estimate -1.11
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.79 +27.44%
on 10/02/19
28.77 -3.48%
on 10/17/19
+1.76 (+6.77%)
since 09/17/19
3-Month
21.79 +27.44%
on 10/02/19
33.18 -16.31%
on 09/09/19
+0.69 (+2.55%)
since 07/17/19
52-Week
11.45 +142.53%
on 10/24/18
33.18 -16.31%
on 09/09/19
+11.06 (+66.19%)
since 10/17/18

Most Recent Stories

More News
Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019

Company also provides an update on plans in nephrology

APLS : 27.85 (-1.10%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.85 (-1.10%)
Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%

Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ANIK : 59.02 (+1.64%)
APLS : 27.85 (-1.10%)
Solidia Technologies Names Doug Robinson CFO and Paul Majsztrik Director of Applied Research

Solidia Technologies(R) announces the appointments of Doug Robinson as chief financial officer and Paul Majsztrik as director of Applied Research. Coupled with recent additions to its Board of Directors,...

APLS : 27.85 (-1.10%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.85 (-1.10%)
Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.85 (-1.10%)
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.85 (-1.10%)
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.85 (-1.10%)
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.85 (-1.10%)
Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.85 (-1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade APLS with:

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the...

See More

Key Turning Points

2nd Resistance Point 30.01
1st Resistance Point 29.08
Last Price 27.85
1st Support Level 26.79
2nd Support Level 25.43

See More

52-Week High 33.18
Last Price 27.85
Fibonacci 61.8% 24.88
Fibonacci 50% 22.32
Fibonacci 38.2% 19.75
52-Week Low 11.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar